AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
EXACOS EG Population
Not yet recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06983340
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD4954Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06980428
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: balcinrenone/ dapagliflozin
- First Posted Date
- 2025-05-19
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06979388
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
Phase 1
Not yet recruiting
- Conditions
- Advanced Chronic Liver DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06974565
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
ESPERANZA: T-DXd Pan-tumor ECA Study
Not yet recruiting
- Conditions
- Bladder CancerBiliary Tract CancerCervical CancerEndometrial CancerOvarian CancerPancreatic CancerColorectal CancerLung CancerOther Tumors
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 576
- Registration Number
- NCT06973161
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
Phase 1
Recruiting
- Conditions
- Advanced Chronic Liver DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT06973005
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3
Not yet recruiting
- Conditions
- Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexateVinblastineDoxorubicinCisplatinGemcitabine
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06960577
- Locations
- πͺπΈ
Research Site, Santiago de Compostela, Spain
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Phase 3
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: PlaceboDrug: Androgen Deprivation Therapy (ADT)Drug: Abiraterone + Prednisolone/Prednisone
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06952803
- Locations
- πΉπ
Research Site, Khon Kaen, Thailand
Tezspire Cardiac Events PASS
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95574
- Registration Number
- NCT06951867
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD4916Other: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 178
- Registration Number
- NCT06951880
- Locations
- π¬π§
Research Site, Harrow, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath